NSE: CARERATING | BSE: 534804

Mid-range Performer

Download real time

1160.40 36.35 (3.23%)

26.14% Fall from 52W High

40,803 NSE+BSE Volume

NSE 15 Apr, 2025 3:31 PM (IST)

3,471.8

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

CARE Ratings Ltd. share price target and research reports

Name: Latest research reports of CARE Ratings Ltd. authored by Rudra Shares and Stock Brokers Ltd and published by - Trendlyne research reports.
Item: CARE Ratings Ltd.
Rating: 5
Author: Rudra Shares and Stock Brokers Ltd

Latest analyst research reports with target prices and PDF download for CARERATING, BSE:534804 CARE Ratings Ltd.

Search Inside the pdf :

CARE Ratings Ltd.

12 Jan 2023

1160.40

3.23%

The Beat

Not Rated: CARE Ratings Ltd.

Prabhudas Lilladhar

CARE Ratings Ltd. is trading below its 50 day SMA of 1166.3

CARE Ratings Ltd.

31 Mar 2020

1160.40

3.23%

CARE Ratings Ltd

Buy: CARE Ratings Ltd.

Target

Rudra Shares and Stock Brokers Ltd

Care being the second largest full service rating Company in India, the Company's list of clients includes banks and other financial institutions, private sector companies, central public sector undertakings, sub-sovereign entities, small and medium enterprises (SMEs) and microfinance institutions, among others. Slowdown in economic growth impacted the company too. The first half of FY20, even Q3 FY20 remained disappointed because of the headwinds faced by the NBFC sector which had impacted the borrowings. And the capex related borrowings not getting the...

CARE Ratings Ltd. is trading above its 30 day SMA of 1132.8

CARE Ratings Ltd.

01 Jan 2020

1160.40

3.23%

CARE RATINGS LTD

Buy: CARE Ratings Ltd.

Target

Rudra Shares and Stock Brokers Ltd

CARE Ratings Ltd. is trading above its 30 day SMA of 1132.8

CARE Ratings Ltd.

14 Jun 2019

1160.40

3.23%

Result Update:CARE Ratings

Results Update: CARE Ratings Ltd.

Axis Direct

Q4FY19 revenues were down ~10% YoY to Rs 89.4cr (up 23% QoQ). Growth in volume of debt rated instruments at 39% was mainly led by bank loan ratings and long term funding. Operating margins have come down to 55%.

CARE Ratings Ltd. is trading below its 50 day SMA of 1166.3

CARE Ratings Ltd.

05 Nov 2018

1160.40

3.23%

CARE

Buy: CARE Ratings Ltd.

Recommendation Target

Centrum Broking

We retain BUY on CARE with revised TP at Rs1,550 (vs. Rs1,600 earlier). Q2'19 revenue / PAT were below estimates. This is even as volume of debt rated grew 32.6% YoY and points to pricing pressure. The growth in high-yielding non-BLR segment remains muted (down 3% YoY for H1'19); we foresee trends to continue in H2'19 and have thus trimmed our overall volume growth assumptions for FY19E. In the backdrop of concerns around rating downgrade / delay in rating changes, CARE has strengthened its rating standards further. We will watch for outcome therein. We like CARE for its business model, return ratios and free cash...

CARE Ratings Ltd. is trading above its 30 day SMA of 1132.8

CARE Ratings Ltd.

08 Oct 2018

1160.40

3.23%

Credit Analysis & Research Ltd.

Not Rated: CARE Ratings Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research CARE Ratings has been the second largest rating company by market share of ~29%. Around 99% (| 322 crore) of its FY18 revenue is generated from the rating segment. However, the recent quarterly...

CARE Ratings Ltd. is trading below its 50 day SMA of 1166.3

CARE Ratings Ltd.

14 Aug 2018

1160.40

3.23%

Credit Analysis & Research Ltd.

Hold: CARE Ratings Ltd.

Target

ICICI Securities Limited

Reported rating revenues of the company witnessed a decline of 6.3% YoY to | 57.4 crore vs. >| 60 crore estimate. This was due to 2.1% YoY decline (after several quarters) in total volume of debt rated to | 382000 crore. Further, corporate/long term bond ratings (which are high yielding in nature) fell 43.5% YoY In Q1FY19, MTM gains on FMPs were lower vs. Q1FY18. This resulted in lower accrual of other income at | 4.2 crore vs. | 6.5 crore last year. Staff cost was higher due to Esop charge of | 3.66 crore...

CARE Ratings Ltd. is trading above its 30 day SMA of 1132.8

CARE Ratings Ltd.

23 May 2018

1160.40

3.23%

Credit Analysis & Research Ltd.

Hold: CARE Ratings Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Reported rating revenues increased above estimate by 21.4% YoY to ~| 94 crore. The growth has been the highest in last several quarters and is led by increased ratings in the short-term debt category The overall quantum of debt rated increased 25% YoY to | 16.48 during FY18. This was due to 7.6% increase in bank loan ratings, 9.4% in long term debt rated and 175.6% in short-term debt rated. The rise in short-term debt rated is mainly due to higher volumes of...

CARE Ratings Ltd. is trading below its 50 day SMA of 1166.3

CARE Ratings Ltd.

05 Feb 2018

1160.40

3.23%

Result Update:CARE Ratings

Buy: CARE Ratings Ltd.

Axis Direct

Revenue grew 13% YoY in Q3 with 19% growth in volume of debt rated. Adjusting for the accounting policy change (refer below), revenue growth was ~20% YoY. Employee costs increased ~40% YoY due to higher ESOP charges and higher employee count resulting in margin compression of ~500 bps YoY to 62%.

CARE Ratings Ltd.'s price crossed above 30Day SMA today

CARE Ratings Ltd.

31 Jan 2018

1160.40

3.23%

Credit Analysis & Research Ltd.

Buy: CARE Ratings Ltd.

ICICI Securities Limited

CARE's revenues were slightly above estimates but the bottomline was below estimate owing to lower other income & higher staff cost Reported rating revenues increased at a healthy rate of 14.2% YoY to | 74.8 crore. The QoQ decline of 18% in rating revenue was owing to surveillance fee income from Q2. There was an 18.2% YoY increase in volume of fresh debt rated in Q3FY18 to | 3.25 lakh crore. In that, volume of bank loan ratings increased 12.1% YoY However, PAT came in at | 37.3 crore (down 2% YoY) vs. estimate of...

CARE Ratings Ltd. is trading above its 30 day SMA of 1132.8

Is CARE Ratings Ltd. worth buying?

172 Votes:

Buy 71.51%

Sell 18.6%

Hold 9.88%